Lilly and Incyte receive marketing approval for RA treatment Olumiant in Japan

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted marketing approval for Olumiant (baricitinib) 2mg and 4mg tablets for the treatment of rheumatoid arthritis (RA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news